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Abstract
Background: Niemann–Pick disease type C is a rare inherited neurodegenerative disease involving impaired
intracellular lipid trafficking and accumulation of glycolipids in various tissues, including the brain. Miglustat, a
reversible inhibitor of glucosylceramide synthase, has been shown to be effective in the treatment of progressive
neurological manifestations in pediatric and adult patients with Niemann–Pick disease type C, and has been used in
that indication in Europe since 2010.
Case presentation: We describe the case of a 16-year-old white French boy with late-infantile-onset Niemann–Pick
disease type C who had the unusual presentation of early-onset behavioral disturbance and learning difficulties
(aged 5) alongside epileptic seizures. Over time he developed characteristic, progressive vertical ophthalmoplegia,
ataxic gait, and cerebellar syndrome; at age 10 he was diagnosed as having Niemann–Pick disease type C based on
filipin staining and genetic analysis (heterozygous I1061T/R934X NPC1 mutations). He was commenced on miglustat
therapy aged 11 and over the course of approximately 3 years he showed a global improvement as well as
improved cognitive and ambulatory function. During this period he remained seizure free on antiepileptic therapy,
using valproate and lamotrigine.
Conclusions: Miglustat improved the neurological status of our patient, including seizure control. Based on our
findings in this patient and previous published data, we discuss the importance of effective seizure control in
neurological improvement in Niemann–Pick disease type C, and the relevance of cerebellar involvement as a
possible link between these clinical phenomena. Thus the therapeutic efficacy of miglustat could be hypothesized
as a substrate reduction effect on Purkinje cells.
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Background
Niemann–Pick disease type C (NP-C) is a rare neurodegen-
erative disease caused by autosomal recessive mutations in
either the NPC1 gene (in 95 % of cases) or the NPC2 gene
[1], resulting in impaired intracellular lipid trafficking and
accumulation of glycolipids in various tissues including the
brain [2]. The diagnosis incidence of NP-C has been re-
ported as 1 case in every 120,000 live births [1].
In clinical terms NP-C is characterized by a range of
symptoms including progressive neurological manifesta-
tions, cognitive and behavioral impairment, and systemic
symptoms [1]. The severity and rate of progression of
NP-C varies with age at neurological disease onset [3].
For this reason it is helpful to regard different clinical
forms of the disease according to agreed age-at-onset
categories: early-infantile (at age 3 months to <2 years),
late-infantile (at age 2 to <6 years), juvenile (at age 6 to
15 years), and adolescent/adult (at age ≥15 years) [1].
Behavioral problems, impaired learning, and delayed or
arrested speech development are usually observed in
patients with neurological disease onset from the juvenile
period onwards [1, 2]. Cognitive impairment with or with-
out psychiatric manifestations usually only appears after a
prolonged period of disease progression, and is most often
recognized in adolescent/adult-onset patients [2, 4].
Epileptic seizures of any type (for example, partial or
generalized, myoclonic, tonic–clonic) and cataplexy are
most often seen in patients with late-infantile-onset
NP-C [1]. While seizures vary markedly among patients
in terms of their intensity and frequency, seizure activity
represents an important clinical management issue in
NP-C because it can have a major impact on a patient’s
quality of life and, in some cases, prognosis [1, 5].
We describe the case of a boy with late-infantile-onset
NP-C who had the unusual presentation of early-onset
behavioral disturbance and learning difficulties; he later
developed epileptic seizures as well as overt neurological
manifestations of NP-C including cerebellar signs and
ophthalmoplegia.
Case presentation
We describe the case of a 16-year-old white French boy
born to unaffected parents in late-1999 following a normal
pregnancy and birth. He displayed normal psychomotor
development up to 4 years of age, with autonomous
walking at 13 months and speech in which he used words
and sentences at 18 months.
At 5 years of age he began to show cognitive slowing
and graphic difficulties (poor drawing) in kindergarten, as
well as motor dyspraxia. Over the next 1.5 years his motor
function deteriorated further with the development of
cerebellar syndrome, and he began to experience partial
seizures primarily affecting his right frontal lobe. These
seizures were treated initially using oxcarbazepine, which
was replaced after 5 months by lamotrigine due to the
appearance of myoclonia. Laboratory analyses for a panel
of metabolic diseases revealed normal urine ammonia
levels, normal plasma acylcarnitine, normal leukocyte acid
hydrolase activities (β-D-galactosidase, hexosaminidases A
and B, arylsulfatase A, β-D-mannosidase), and normal
copper levels. Chromatographic urine analysis showed
normal levels of organic acids and oligosaccharides.
G-band karyotype analysis showed normal findings, and
an FMR1 gene study ruled out fragile X syndrome.
Follow up at 9 years of age showed further cognitive
deterioration, categorized as a frontal syndrome (echolalia,
behavioral perseveration) and progressive loss of expres-
sive language. His cerebellar syndrome had worsened,
with occurrence of an ataxic gait and dysmetria, and he
displayed pyramidal syndrome. He was presenting several
epileptic seizures daily. He had also begun to be incontinent
for urine and feces.
Brain magnetic resonance imaging (MRI) did not identify
any abnormalities, but an ophthalmic examination revealed
vertical supranuclear gaze palsy (VSGP), and analysis of per-
ipheral blood and bone marrow biopsies identified
vacuolated histiocytes. Together, these findings prompted
biochemical and genetic testing for suspected NP-C in early
2010, which was approximately 5 years before this report.
Filipin staining in cultured skin fibroblasts identified
cholesterol-rich perinuclear vesicles. Plasma oxysterols (cho-
lestan-3β,5α,6β-triol) have not been tested for this patient.
Sequencing of the complete coding sequences and intronic
junctions of NPC1 and NPC2 genes was done by Sanger
method on genomic deoxyribonucleic acid (DNA) extracted
from his fibroblasts (used for the filipin test). Two deleteri-
ous heterozygous mutations in NPC1 (reference transcript
NM_000271.4) were found: p.Arg934* (c.2800C>T) in exon
19 (Fig. 1a) and p.Ile1061Thr (c.3182T>C) in exon 21
(Fig. 1b). The independent segregation of the two mutations
was demonstrated by studying his parents’ DNA obtained
from blood samples.
So, he had a typical compound heterozygote NP-C
genotype: I1061T/R934X.
Soon after diagnosis he was hospitalized in early 2010
following two episodes of aspiration-related pneumonia. A
speech therapist examination identified frequent aspiration
of liquids, sialorrhea/frequent drooling, a weakened gag
reflex, and slow swallowing and ingestion of solid food. A
gastrostomy tube was placed approximately 1 month later.
He scored 9/9 (restricted to a wheelchair) on the Hauser
Standard Ambulation Index (SAI), 17 out of a possible
maximal severity score of 18 on the NP-C disability scale
proposed by Iturriaga et al. [6], and a maximal severity
score of 1.0 on the modified disability scale reported by
Pineda et al. [7]. A follow-up ophthalmological evaluation
was not possible as our patient had complete ophthalmo-
plegia. His brain MRI findings were normal.
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Treatment with miglustat (Zavesca®; Actelion Pharma-
ceuticals Ltd) was commenced in February 2010, and he
received approximately 2.5 years of uninterrupted ther-
apy at a dose of 100 mg three times a day based on his
body surface area (as per manufacturer’s recommenda-
tions) [8]. At the commencement of therapy he experi-
enced initial, transient abdominal pain and frequent
diarrhea that were treated using loperamide 1 mg twice
a day. He was initiated on a diet excluding disaccharides
following consultation with a specialist dietician, and his
feeding and caloric intake have since been monitored
regularly by a gastropediatrician.
Electroencephalographic evaluation indicated infracli-
nical brain function abnormalities (spike waves) predom-
inantly affecting his left temporal lobe. Motor and
sensory nerve conduction velocities were normal. His
epilepsy appeared to be well controlled in late-2010. He
was at that time receiving a combination of sodium
valproate (400 mg three times a day; 30 mg/kg/day) and
lamotrigine (100 mg in the morning and 50 mg in the
evening; 4 mg/kg/day for 16 months). He became seiz-
ure free in June 2010, 4 months after beginning the
miglustat treatment.
At clinical assessment in May 2012 (approximately 3
years before this presentation), at 12.5 years of age,
following approximately 2.5 years of miglustat therapy, a
global improvement was recorded. His body weight had
increased and he had not experienced an epileptic
seizure for approximately 2 years (since May 2010),
which seemed to coincide with the time at which good
digestive tolerance to miglustat therapy was achieved.
He showed improvements in cognition (reacquisition of
a few words) and motor function, and was ambulating
with a walker, scoring 5 on the SAI: he was able to walk
7.62 m (25 feet) in <20 seconds using a walker. He dis-
played ataxic, stop-start ambulation, dysmetria, and
upper limb apraxia; his ophthalmoplegia remained un-
changed. A repeat brain MRI examination showed
bilateral atrophy of his cerebellar vermis and diffuse
white matter hyperintensities in T2-weighted images
(Fig. 2a, b). He was therefore scheduled for full clinical
assessment in line with international clinical recommen-
dations in order to reassess his miglustat dose based on
a judgment of efficacy versus safety.
At further follow up he scored 14 on the Iturriaga et al.
NP-C disability scale [6], and 0.7 on the modified disability
scale published by Pineda et al. [7]. Since his body weight
had reached 40 kg, corresponding to a body surface area
of 1.28 m2, the miglustat dose was increased from 100 mg
three times a day to 200 mg three times a day according
to the French recommendations for the use of miglustat
in children with NP-C.
Fig. 1 a NPC1 gene – exon 19: mutation c.2800C>T heterozygous (p.Arg 934*). b NPC1 gene – exon 21: mutation c.3182T>C heterozygous (p.Ile1061Thr)
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Discussion
In NP-C, mutations in the NPC1 gene give rise to
impaired intracellular lipid trafficking and subsequent
accumulation of unesterified cholesterol, sphingosine,
and a range of glycosphingolipids in various tissues
including the brain [2]. The cerebellum plays an im-
portant role in NP-C, as neuronal loss is more prom-
inent compared with other brain areas, and outputs
from the cerebellum operate in both the motor and
cognitive domains [9]. GABAergic cerebellar Purkinje
cells appear particularly susceptible to damage in
NP-C. Based on data from a feline NP-C model, Stein
et al. proposed that miglustat – a reversible inhibitor
of glucosylceramide synthase, the enzyme that cata-
lyzes the first step in the biosynthesis of most glycolipids
in NP-C – might improve neurological function due partly
to improved Purkinje cell survival [10].
Learning disabilities observed in the nursery school
setting can be the first manifestations of the late-infantile
form of NP-C, as observed in our patient. However, this
case was slightly unusual in that patients with NP-C do
not generally present with cognitive impairment and/or
behavioral problems so early in life, certainly not during
the late-infantile period [1, 2]. Cognitive deterioration is
usually first observed during adolescence or early-
adulthood [1, 2, 4].
This case also highlights the importance of achieving
effective control of epilepsy in patients with NP-C.
Seizures can have a notable impact on a patient’s quality
of life and general health status, and usually result in
worsening patient scores on the NP-C disability scale,
which assesses four key parameters of neurological dis-
ease progression: ambulation, manipulation, language,
and swallowing [1, 6, 7]. In fact, patients with frequent
and/or severe seizures are considered to have a poor
overall prognosis [1].
Skorpen et al. reported the case of a patient with
p.S940L-homozygous late-infantile-onset NP-C whose
quality of life and neurologic condition initially improved
with miglustat [5]. However, follow up 18 months after
commencing miglustat therapy, at which point the patient
was experiencing very frequent epileptic attacks, indicated
a general loss of energy and deterioration of neurological
status, and a worsening of scores on the modified disabil-
ity scale from 0.63 to 0.90 at the peak of epileptic activity.
When control of seizure epilepsy was re-established 4
months later, a repeat assessment indicated a return
toward neurological stability (disability scale score 0.71)
[5]. Based on these observations the authors emphasized
the importance of seizure control therapy in achieving
and maintaining neurological stabilization.
Similar findings were reported based on a prospect-
ive study of miglustat therapy in a French NP-C
cohort, which included eight patients with the early-
infantile form, eight with the late-infantile form, and
three with the juvenile-onset form of the disease (our
patient was included as patient 17 in this overall
cohort) [11]. While neurological deterioration was
seen to commence in one patient at the time his
seizures became refractory to antiepileptic medication,
pre-existing epilepsy (before miglustat therapy) or the
onset of epilepsy during miglustat therapy did not
appear to affect neurological outcomes in cases where
seizure control was maintained using antiepileptic
medications [11]. In our patient, the antiepileptic
therapy using valproate and lamotrigine showed no
efficacy for more than 1 year; however, our patient’s
condition dramatically improved after miglustat ther-
apy was started and he became seizure free 4 months
after its introduction. This chronology of events
seems to be suggestive of the efficacy of miglustat
rather than the antiepileptic therapy alone.
Fig. 2 Magnetic resonance imaging scan from patient with late-infantile-onset Niemann–Pick disease type C. The magnetic resonance
imaging scan shows: a vermian atrophy on T2-weighted sequence, May 2012 and; b diffuse white matter hyperintensities on fluid-attenuated inversion
recovery sequence (FLAIR), May 2012
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Miglustat has been shown to stabilize neurological
manifestations in children with NP-C, particularly
among those with late-infantile or juvenile-onset disease
[7, 11]. Our patient, who has received uninterrupted
treatment with miglustat for approximately 3 years,
showed improved neurological status (reacquisition of
verbal speech and indoor assisted ambulation) after 5
months on miglustat therapy, and has remained free of
seizure activity. He remains neurologically stable to date,
despite showing evidence of vermian atrophy and diffuse
white matter hyperintensities in T2-weighted images
during a brain MRI assessment in May 2012 (after 15
months of miglustat therapy). This seems consistent
with previous data from longitudinal imaging studies in
pediatric patients with NP-C, which indicated no clear
relationship between MRI or magnetic resonance spec-
troscopy (MRS) findings and clinical disease course
during miglustat therapy [11–13].
On the basis of this case, it is interesting to specu-
late whether early-onset behavioral/cognitive deteri-
oration may be partly related to seizure activity in
NP-C. Further, it might be pertinent to investigate
whether the therapeutic effects of miglustat in NP-C
might be related, at least in part, to the improved
survival of neuronal cerebellar substrates associated
with both cognitive function and seizures. In this
respect, it seems relevant to note that cerebellar grey
matter volume has been shown to be reduced in
patients with generalized tonic–clonic seizures [14],
and that there is evidence to suggest that altered
cerebellar GABAergic neurotransmission can affect
both seizure activity and cognitive/behavioral func-
tion [15].
Conclusions
Miglustat in our patient with late-infantile-onset NP-C
has improved neurological manifestations and may
have contributed to improve his epileptic status, since
seizure control occurred after its initiation. We
hypothesize a common cerebellar implication in both
cognitive/behavior disturbances and seizure activity,
and thus a possible therapeutic effect of miglustat by
a substrate reduction therapy on Purkinje cells. How-
ever, as suggested by Stein et al., miglustat could
improve neurological manifestations of NP-C disease
by other mechanisms, including reduced glycosphin-
golipid accumulation in the brain, and modulation of
microglial immunophenotype and function [10].
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